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Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disease due mainly to inherited deficiencies
in the proteins or enzymes involved in the clearance of triglycerides from circulation. It usually happens in late
childhood and adolescence, which can have serious consequences if misdiagnosed or untreated. In the present
study, we investigated two Chinese male babies (A and B), 30d and 48d in age, respectively, who have milky
plasma. Clinical, biochemical, and radiological assessments were performed, while samples from the patients were
referred for molecular diagnosis, including genetic testing and subsequent analysis of related genes. The fasting
serum lipids of the two patients showed extreme lipid abnormalities. Through a low-lipid formula diet including
skimmed milk and dietary advice, their plasma lipid levels were significantly lower and more stable at the time of
hospital discharge. The genetic testing revealed compound heterozygote mutations in the lipoprotein lipase (LPL)
gene for patient A and two known compound heterozygote LPL gene mutations for the patient B. FCS is the
most dramatic example of severe hypertriglyceridemia. Early diagnosis and timely dietary intervention is very
important for affected children.
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Familial chylomicronemia syndrome (FCS) is a rare
autosomal recessive disease which is a genetic defect of
the intravascular lipolysis of triglyceride (TG)-rich lipo-
proteins. It is characterized by very severe hypertriglyc-
eridemia, recurrent abdominal pain, episodes of acute
pancreatitis, eruptive cutaneous xanthomata, and lipe-
mic (“lactescent or milky”) plasma. Mutations causing
FCS have been found in the following genes: lipoprotein
lipase (LPL), apolipoprotein AV (APOA5), apolipopro-
tein CII (APOC2), lipase maturation factor 1 (LMF1),
and glycosyl-phosphatidylinositol anchored high-density
lipoprotein-binding protein 1 (GPIHBP1) [1]. It is docu-
mented in most cases with FCS due to mutations in the* Correspondence: Gaorui@genomics.cn; zhangyongjun@sjtu.edu.cn
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of genes encoding proteins related to LPL functioning:
APOA5, APOC2, LMF1 and GPIHBP1 [2]. Familial LPL
deficiency usually manifests by 10 years of age, and in
25 % occurs during infancy [3].Patients and methods
Patients
The parents of the patients were given informed consent.
Approval of the ethics committee of Xin Hua Hospital
had been obtained before the study was initiated.
Patient A is a Chinese male baby, the second neonate
of unrelated parents delivered by cesarean section after a
full-term uneventful pregnancy. The birth weight was
3650 g. The baby remained clinically well. He was first
noted to have lipemic serum at 30 days of age when
blood drawn for a complete blood count could not be
analyzed because of the turbidity of the serum. Physical
examinations reported a well-developed child, with head
circumference of 38.8 cm, and weighing 6000 g. Inis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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ever, eruptive xanthomatas was noted on the scalp, face
and lower limbs. Blood chemistry showed a plasma con-
centration of total cholesterol and total triglyceride were
abnormal (Table 1), amylase and lipase were still within
the normal range. The baby had been exclusively breast-
fed since birth. The plasma lipid levels of his parents
and brother were normal. Family history was unremark-
able. The first therapeutic measure was a low-lipid for-
mula diet including skimmed milk and dietary advice.
Patient B is a Chinese male baby, who was born at 36
(+5) weeks by cesarean section, weighing 2800 g. The
baby was observed for neonatal mild jaundice until
5 days of age. He was initially admitted to the hospital
for choking on milk and for polypnea at 48 days of age.
During sampling, the venous blood was remarkably
pink-creamy colored. Physical examination was negative
with no dysmorphic features or skin lesions, with satis-
factory general conditions. Body fat distribution was nor-
mal. His head circumference was 35 cm and weight was
4720 g. Blood chemistry showed plasma levels of choles-
terol and triglyceride were high abnormally (Table 1),
amylase and lipase were still within the normal range.
The liver and spleen were not enlarged. The baby was
also on exclusive breastfeeding since birth. Parents were
healthy with normal serum lipid and lipoprotein levels.
No positive family history of hyperlipidemia was known.
Further laboratory investigations in both cases showed
normal glucose and thyroid, liver, and kidney function.
Cardiovascular examinations, including electrocardio-
gram (ECG) and baseline echocardiogram (ECHO), as
well as the ophthalmoscopic examination and cerebral
and abdominal ultrasound examinations were negative.
A thorough history, physical examination, and laboratory
workup failed to identify a clear etiology of the ex-
tremely abnormal blood lipid level, prompting genetic
investigation to identify the genetic cause of the milky
serum.
Clinical and laboratory data
Clinical, biochemical, and radiological assessments were
undertaken in Xin Hua Hospital. The lipid level was
analyzed repeatedly and at the time of discharge from
the hospital.Table 1 Comparison of lipid profile for patients before and after tre
Patient A





TGD triglyceride, CHO cholesterol, HDL high-density lipoprotein, LDL low-density lipGenetic analyses
Genomic DNA was extracted from peripheral blood
leukocytes using standard method. A customized oligo-
nucleotide probe (Nimblegen SeqCap EZ Solution) was
designed to capture translated regions (exons, 50 bp ex-
tending in both directions) of forty-three genes for
mono-dyslipidemia panel on conclusions from genome
association studies, linkage studies, and the use of ani-
mal models [4]. Capture was performed according
DNA broken, library preparation and hybridization.
Then sequenced on Illumina HiSeq2500 Analyzers as
PE 90 bp reads, providing an average depth of at least
100-fold for one sample. Sequenced reads were aligned
to the GRCh37/hg19 human reference genome (UCSC
Genome Browser) with the Burrows-Wheeler Aligner
(BWA, v.0.6.2) [5]. SNVs and small insertions and dele-
tions were called using Genome Analysis Toolkit (GATK,
v.2.5.2). CNVs were assessed by read depth (RD).
Results
Clinical diagnosis and treatment
Upon admission, severe dietary triglyceride restriction
but no lipid-lowering drug was used to treat the babies.
Compared with the lipid profile at the time of admission,
the lipid profile of patients after treatment lowered,
which is summarized in (Table 1).
Molecular diagnosis
We performed target region capture sequencing of the
mono-dyslipidemia panel on two pedigrees to identify the
genetic cause of the milky blood. For all subjects, the over-
all coverage of the target region was above 97 % for a
minimum depth of 30X and the average sequencing depth
was above 400-fold. Variants on genes known to cause
chylemia (LPL, APOC2, APOA5, LMF1, and GPIHBP1)
were first selected and interpreted. In the case of patient
A, genetic testing revealed compound heterozygote muta-
tions (c.809G >A p.Arg270His, c.1262G >A p.Trp421*) in
the LPL gene. And a pedigree study shows that the pro-
band’s father was carrier of c.809G > A (p.Arg270His) mu-
tation, meanwhile his mother and brother were carriers of
c.1262G >A (p.Trp421*) mutation (Fig. 1a). For patient B,
genetic testing revealed two known compound het-
erozygote LPL gene mutations: a missense mutationatment
Patient B Normal range






Fig. 1 Partical nucleotide sequence of LPL gene in the probands. a KD-4 (proband A) was found compound heterozygosity of p.Arg270His and
p.Trp421* mutations on LPL gene. Left: Chromatogram of DNA sequence analysis of LPL gene mutations. Arrow indicates the mutation site. KD-4
and KD-1 (father of proband A) were heterozygous for c.809G > A, KD-2 (mother of proband A) and KD-3 (brother of proband A) were normal.Right:
KD-2, KD-3, KD-4 were heterozygous for c.1262G > A and KD-1 was normal. b Chromatogram of DNA sequence analysis of LPL gene mutations. Arrow
indicates the mutation site. KD-7 (proband B) and KD-6 (father of proband B) were heterozygous for c.836T > G, KD-5 (mother of proband B) as normal
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letion (deletion of exon8-exon10) (Fig. 2a). Pedigree
analysis shown that the c.836 T > G (p.Leu279Arg)
mutation was from his father and the large fragment
deletion was from his mother. The missense muta-
tion of patient B was confirmed by Sanger sequence
(Fig. 1b). The large fragment was configured by
qPCR (Fig. 2b).
Discussion
FCS is defined as severe hypertriglyceridemia and fast-
ing accumulations of chylomicrons in plasma, and the
risk of recurrent and potentially fatal pancreatitis and
other complications [1]. FCS is characterized by severe
hypertriglyceridemia with episodes of eruptive cutane-
ous xanthomas, abdominal pain, hepatosplenomegaly,
recurrent acute pancreatitis, and lipemia retinalis [6]. Itusually manifests in late childhood and adolescence,
but evidence suggests that presentation during infancy
can be hetergeneous. It may include other signs such as
anemia, jaundice, irritability, diarrhea, and pallor. These
manifestations vary in time and severity. Ahmad re-
ported a case about an infant attacked by FCS who suf-
fered from severe complications, which highlights the
need to pursue a genetic evaluation in the absence of
secondary causes of severe hypertriglyceridemia in in-
fants [7]. Besides the biochemical tests, genetic testing
used on the susceptible population with positive family
history of hyperlipidmia could enhance early diagnosis.
In addition, close clinical follow-up and laboratory
monitoring could be performed to get information
about the level of lipids, and thus the occurrence of
some complications would be detected without delay.
APOC3 is a glycoprotein that is synthesized principally
Fig. 2 A missense mutation and a large fragment deletion in proband B. a The average RDs of all exons in LPL. Upper left: The average RDs of all
exons in LPL from NGS showing normal sequence from a control individual. Upper right: The average RDs of all exons in LPL from KD-6 (father of
proband B) showing no mutation. Bottom Left: The average RDs of all exons in LPL from KD-5 (mother of proband B) showing that there is a
large fragment deletion (exon8-exon10). Bottom Right: The average RDs of all exons in LPL from KD-7 (proband B) showing that there is a large
fragment deletion (exon8-exon10). b Sgdv1n132*10 was the control of QPCR for exon8-exon10. The result showing that KD-6 was normal, KD-5
and KD-7 were large fragment deletion carriers
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proteins and HDL, which has been reported to be a po-
tent inhibitor of the activation of LPL [8]. Volanesorsen
is an antisense inhibitor of APOC3 synthesis, which has
been extensively evaluated in several animal models on
different diets in Phase 1 and Phase 2 clinical trials, and
is currently being evaluated for triglyceride reduction in
two Phase 3 randomized, placebo-controlled trials in
patients with FCS and familial partial lipodystophy [9].
There are some other lipid-lowering agents such as
DGAT1 inhibitor pradigastat evaluated in FCS patients
[10]. For the treatment, there was increasing evidence
suggesting the effectiveness and short-term safety of
the triglyceride-lowering agents in children similar to
those in adults. Long-term studies are still needed to
ensure the safety and effectiveness of these agents in
children [11]. In our cases, the babies were switched to
dietary restraints with no lipid-lowering drug and the
level of lipids soon decreased. If the lipid-lowing agents
and an extremely low-fat diet could not be enough to
reduce the concentrations of chylomicrons and triglycer-
ide, nonpharmacological approaches based upon plasma-
exchange (PEX) can remove triglyceride from plasma to
improve the clinical conditions of patients with sHTG [2].
Timely dietary modification could improve the prognosis
and maintain a normal lifestyle for affected children, by
reducing the risk of some complications.
In our cases, genetic investigation could help to iden-
tify the etiology of infants with milky serum for the het-
erogeneity of FCS in the young group. For patient A,the genetic testing has revealed compound heterozy-
gote mutations (c.809G > A p.Arg270His, c.1262G > A
p.Trp421*) in the LPL gene (Fig. 1a). Both of the muta-
tions were well-studied. A patient with a homozygous
R270H in the LPL has been previously described [12].
Expression studies in COS-1 cells showed that the
product of the mutated LPL (243 amino acids as op-
posed to 270 in our case) had a marked reduction in
expressed mass in media and cell homogenate (24 %
and 61 %). Additionally, it had no measurable level of
lipolytic activity in cells or medium [13]. The nonsense
mutation (c.1262G > A p.Trp421*) changes Tryptophan
421 to a stop codon (W421X), which is predicted to
truncate LPL from its expected 448 AA in the mature
protein to 421 AA. In vitro studies showed that Trp421
is important for the binding of lipoprotein lipase to li-
poproteins [14]. For patient B, genetic testing revealed
two known compound heterozygote LPL gene muta-
tions: a missense mutation (c.836T > G p.Leu279Arg)
and a large fragment deletion (deletion of exon8-
exon10) (Fig. 2a). In vitro site-directed mutagenesis and
expression in COS cells showed that Leu252Arg mu-
tant LPL was associated with reduced LPL mass (32 %
of the normal) and no LPL catalytic activity (0 %) [15].
A patient with the homozygous mutation of exon8-
exon10 deletion has been described previously [16]. Pedi-
gree analysis showed that the c.836T >G (p.Leu279Arg)
mutation was from his father and the large fragment dele-
tion was from his mother (Fig. 1b). The large fragment
was configured by qPCR (Fig. 2b).
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We should pay more attention to the early diagnosis of
the infants with FCS. Severe and timely dietary triglycer-
ide restriction is one of the most effective treatment mo-
dalities for affected children. The patients should be
observed with close follow-ups in future.
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